Newspaper publication for audited financial result for the quarter and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Checkpoint Trends Limited (formerly Rubra Medicaments Limited, scrip code 531099) has submitted copies of newspaper advertisements of its audited financial results for Q4 FY25 and FY25 ended March 31, 2025, originally published in Business Standard and Mumbai Lakshadeep on May 31, 2025. For FY25, total income from operations rose to Rs. 4,163.37 lakhs from Rs. 3,487.00 lakhs in FY24 (about 19.4% growth), while net profit after tax more than doubled to Rs. 38.58 lakhs from Rs. 18.25 lakhs. For Q4 FY25, total income stood at Rs. 1,328.44 lakhs versus Rs. 1,008.88 lakhs in Q4 FY24, with net profit after tax at Rs. 12.25 lakhs (vs Rs. 9.81 lakhs). EPS for FY25 was Rs. 0.42 versus Rs. 0.20 in FY24, and net worth stood at Rs. 1,528.43 lakhs. The results were approved by the Board on May 30, 2025.
The doubling of annual profit along with ~19% revenue growth signals improving business performance for shareholders, though the company's small scale (Rs. 4 crore revenue) limits broader market impact and liquidity in the stock.